OpenAI buys Orchestra Bio to add drug agents to Rosalind

OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is bringing its team and technology into Rosalind, OpenAI’s AI models and tools for life sciences research, the company said Tuesday. OpenAI did not disclose the price or terms.

Orchestra is led by founder and CEO Ashoka Rajendra, according to Orchestra’s website and 8VC, which led the startup’s Series A.

Why it matters

On Orchestra’s platform, scientists and program leaders hand the monitoring and tracking of studies to AI agents, OpenAI said. A failed manufacturing batch, for example, can delay the start of a clinical trial, and Orchestra’s agents help teams find which activities and timelines are affected and compare ways to respond, according to OpenAI.

Developing a new medicine takes roughly 10 to 15 years on average from target discovery to regulatory approval in the United States, OpenAI said.

Who has a stake

OpenAI named Novo Nordisk and Moderna as partners in its life sciences work. Rosalind includes GPT-Rosalind, which helps scientists reason through biology and chemistry questions, and Rosalind Workbench, which connects those capabilities with scientific tools and data, according to the company.

8VC said it led Orchestra’s Series A last year and named Andy Xu as the startup’s chief technology officer.

What’s next

OpenAI said it aims to build agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.